Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

被引：0
|
作者：
George S. Laszlo
Todd A. Alonzo
Chelsea J. Gudgeon
Kimberly H. Harrington
Alex Kentsis
Robert B. Gerbing
Yi-Cheng Wang
Rhonda E. Ries
Susana C. Raimondi
Betsy A. Hirsch
Alan S. Gamis
Soheil Meshinchi
Roland B. Walter
机构：
[1] Clinical Research Division,Department of Biostatistics
[2] Fred Hutchinson Cancer Research Center,Department of Pediatrics
[3] University of Southern California,Department of Pathology
[4] Children’s Oncology Group,Department of Laboratory Medicine and Pathology
[5] Molecular Pharmacology and Chemistry Program,Division of Hematology
[6] Sloan Kettering Institute,Oncology
[7] Memorial Sloan Kettering Cancer Center,Department of Pediatrics
[8] Weill Medical College of Cornell University,Department of Medicine, Division of Hematology
[9] St. Jude Children’s Research Hospital,Department of Epidemiology
[10] University of Minnesota Cancer Center,undefined
[11] Children’s Mercy Hospitals and Clinics,undefined
[12] University of Washington,undefined
[13] University of Washington,undefined
[14] University of Washington,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 29 条
  • [1] High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
    George S. Laszlo
    Todd A. Alonzo
    Chelsea J. Gudgeon
    Kimberly H. Harrington
    Alex Kentsis
    Robert B. Gerbing
    Yi-Cheng Wang
    Rhonda E. Ries
    Susana C. Raimondi
    Betsy A. Hirsch
    Alan S. Gamis
    Soheil Meshinchi
    Roland B. Walter
    Journal of Hematology & Oncology, 8
  • [2] High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
    Laszlo, George S.
    Alonzo, Todd A.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Kentsis, Alex
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Ries, Rhonda E.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Gamis, Alan S.
    Meshinchi, Soheil
    Walter, Roland B.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [3] High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
    Laszlo, George S.
    Alonzo, Todd A.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Kentsis, Alex
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Ries, Rhonda E.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Gamis, Alan S.
    Meshinchi, Soheil
    Walter, Roland B.
    BLOOD, 2015, 126 (23)
  • [4] High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group (vol 8, 115, 2015)
    Laszlo, George S.
    Alonzo, Todd A.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Kentsis, Alex
    Gerbing, Robert B.
    Wang, Yi-Cheng
    Ries, Rhonda E.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Gamis, Alan S.
    Meshinchi, Soheil
    Walter, Roland B.
    Journal of Hematology & Oncology, 2016, 9
  • [5] High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype
    Xu, Xiaoyu
    Zeng, Zhao
    Huo, Li
    Liu, Hong
    Yu, Yan
    Zhang, Ling
    Cen, Jiannong
    Qiu, Huiying
    Tang, Xiaowen
    Fu, Chengcheng
    Han, Yue
    Miao, Miao
    Jin, Zhengming
    Ruan, Changgeng
    Wu, Depei
    Chen, Suning
    Wang, Qinrong
    Yan, Lingzhi
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (01) : E23 - +
  • [6] High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
    Laszlo, George S.
    Ries, Rhonda E.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Gamis, Alan S.
    Meshinchi, Soheil
    Walter, Roland B.
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2817 - 2821
  • [7] MYOCYTE-SPECIFIC ENHANCER BINDING FACTOR 2C (MEF2C) EXPRESSION IN THE DENTATE GYRUS DURING DEVELOPMENT AND AFTER PILOCARPINE-INDUCED STATUS EPILEPTICUS A preliminary report
    Scorza, Carla Alessandra
    Cavalheiro, Esper Abrao
    Scorza, Fulvio Alexandre
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2008, 66 (3B) : 731 - 735
  • [8] Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements
    Menshawy, Nadia El
    El-Ghonemy, Mohamed S.
    Ebrahim, Mohamed A.
    Fahmi, Maryan Waheeb
    Saif, Maha
    Denewer, May
    El-Ashwah, Shaimaa
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2355 - 2364
  • [9] TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group
    Kutny, Matthew A.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Geraghty, Daniel
    Gamis, Alan S.
    Lange, Beverly
    Heerema, Nyla A.
    Franklin, Janet
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Meshinchi, Soheil
    BLOOD, 2011, 118 (21) : 262 - 262
  • [10] CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children's Oncology Group Report
    Schuback, Heather L.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Miller, Kristen L.
    Kahwash, Samir
    Heerema-Mckenney, Amy
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Aplenc, Richard
    Gamis, Alan S.
    Meshinchi, Soheil
    BLOOD, 2014, 124 (21)
123